The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

20131203_14

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS
Issue 44 – Nov. 22, 2013PDF

example

ASCO Vying for Big Role in Big Data

Conversation with The Cancer Letter: ASCO President Clifford HudisThe American Society of Clinical Oncology is in the final stages of developing a request for proposals for its CancerLinQ system. The RFP is expected to be issued early in 2014.
photoBiospecimen Banks Program for NCTNMoves Forward With Approval From BSAAs NCI digs out after the two-week shutdown of the federal government, its leadership has to contend with the prospect of another shutdown weeks away, which may kick in after the current continuing resolution expires Jan. 15, 2014.
photoPiotr Kulesza, 46, Pathologist At Northwestern,ECOG-ACRIN, Dies in Fall After Group MeetingPiotr Kulesza, a pathologist at Northwestern University Robert H. Lurie Cancer Center, who worked with the ECOG-ACRIN Cancer Research Group, died after a fall from a hotel balcony after attending the cooperative group’s semi-annual meeting. Kulesza was 46.
photo
In Brief

YOU MAY BE INTERESTED IN

ClinicalTrials & Tribulations

How GLP-1RA drugs are reshaping patient physiology and the future of oncology

The rapid adoption of glucagon-like peptide-1 receptor agonists (GLP-1RAs), particularly for weight management, represents one of the most significant shifts in metabolic medicine in decades. With millions of people now using medications such as semaglutide and tirzepatide, we are witnessing a fundamental alteration in patient physiology that extends far beyond glucose control and weight loss. As these drugs approach 10% population penetrance in some demographics, the oncology community faces an urgent question: How will this metabolic transformation reshape cancer care?
By Deborah Phippard

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account